“but someone who is not completely fluent in the language, much less corporate language, should not be writing PRs at this point.”

IMO, what you stated above isn’t the main cause of the issue. The main cause is that NP is very much a salesman and this issue is portrayed in the way he presents information. This has been demonstrated numerous times in interviews and CCs when he continually recites how far CYDY and leronlimab have come, how many shares he didn’t dilute, the tone of his voice and so on. He then writes PRs in a similar manner, trying to sell data, when he should let the science speak for himself.